{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:38:07Z","timestamp":1792715887542,"version":"4.5.0"},"reference-count":21,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2016,1,21]],"date-time":"2016-01-21T00:00:00Z","timestamp":1453334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Lab Hematology"],"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Detection of mutations in the myeloid differentiation primary response gene 88 (MYD88) has clinical implications on diagnosis and therapy, especially in patients with Waldenstr\u00f6m's macroglobulinemia (WM) and IgM monoclonal gammopathy of unknown significance (IgM\u2010MGUS). We describe a method that provides greatly increased sensitivity for detecting minority mutations in MYD88.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We used a locked nucleic acid oligonucleotide to block amplification of wild\u2010type DNA during polymerase chain reaction (PCR). Sanger sequencing of amplified DNA was used for detecting mutations in MYD88 gene. This approach was used to test samples from patients with WM and IgM\u2010MGUS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>When compared to traditional PCR followed by Sanger sequencing, our methodology was significantly more sensitive (one mutant allele in a background of 200 wild\u2010type alleles). Using sequencing allowed us to visualize the PCR product, giving advantages over other methodologies such as allele\u2010specific PCR. Based on analyzing 36 randomly selected, MYD88 mutated, clinically tested samples, we demonstrate that traditional PCR failed to detect MYD88 mutations in 64% of the samples that were clearly positive by wild\u2010type blocking PCR.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The new methodology is essential for attaining accurate results in clinical testing.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ijlh.12456","type":"journal-article","created":{"date-parts":[[2016,1,21]],"date-time":"2016-01-21T16:56:34Z","timestamp":1453395394000},"page":"133-140","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Positive selection and high sensitivity test for MYD88 mutations using locked nucleic acid"],"prefix":"10.1111","volume":"38","author":[{"given":"A.","family":"Albitar","sequence":"first","affiliation":[{"name":"NeoGenomics Laboratories Irvine CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Ma","sequence":"additional","affiliation":[{"name":"NeoGenomics Laboratories Irvine CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"DeDios","sequence":"additional","affiliation":[{"name":"NeoGenomics Laboratories Irvine CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Estella","sequence":"additional","affiliation":[{"name":"NeoGenomics Laboratories Irvine CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Agersborg","sequence":"additional","affiliation":[{"name":"NeoGenomics Laboratories Irvine CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Albitar","sequence":"additional","affiliation":[{"name":"NeoGenomics Laboratories Irvine CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,1,21]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.icb.7100095"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.004465"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200710"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09671"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-457101"},{"key":"e_1_2_6_7_1","doi-asserted-by":"crossref","unstructured":"SalarA Garcia\u2010PallarolsF Fern\u00e1ndez\u2010Rodr\u00edguezC S\u00e1nchez\u2010Gonz\u00e1lezB VelaMC GimenoE PairetS SeninA CamachoL SerranoS BessesC BellosilloB:1690 MYD88 (L265P) Mutation Confers Very Poor Response and Outcome after Second\u2010Line Therapy in Patients with Diffuse Large B\u2010Cell Lymphoma (DLBCL). Presentation at 56th American Society of Hematology Meeting and Exposition San Francisco CA 2014.","DOI":"10.1182\/blood.V124.21.1690.1690"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.892"},{"key":"e_1_2_6_9_1","doi-asserted-by":"crossref","unstructured":"WangD JiangW SullivanT BhagatL:508 Novel Approach to the Potential Treatment of Patients with B\u2010Cell Lymphomas Harboring the MYD88 L265P Mutation: Combination Treatment with TLR Antagonist and Rituximab. Presentation at 56th American Society of Hematology Meeting and Exposition San Francisco CA 2014.","DOI":"10.1182\/blood.V124.21.508.508"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-454355"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23192"},{"key":"e_1_2_6_12_1","first-page":"53","article-title":"Emerging targets in human lymphoma: targeting the MYD88 mutation","volume":"3","author":"Wang JQ","year":"2013","journal-title":"Blood Lymphat Cancer"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208832"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6890-4-1"},{"key":"e_1_2_6_15_1","first-page":"257","article-title":"EGFR and K\u2010ras mutation analysis in non\u2010small cell lung cancer: comparison of paraffin embedded versus frozen specimens","volume":"29","author":"Gallegos Ruiz MI","year":"2007","journal-title":"Cell Oncol"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms12053191"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gks299"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2012.202390"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.503"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00286715"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/12.14.5869"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1987.tb11200.x"}],"container-title":["International Journal of Laboratory Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijlh.12456","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijlh.12456","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T17:18:44Z","timestamp":1695489524000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijlh.12456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,21]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1111\/ijlh.12456"],"URL":"https:\/\/doi.org\/10.1111\/ijlh.12456","archive":["Portico"],"relation":{},"ISSN":["1751-5521","1751-553X"],"issn-type":[{"value":"1751-5521","type":"print"},{"value":"1751-553X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,21]]}}}